Related references
Note: Only part of the references are listed.BRAF-Driven Pancreatic Cancer: Prevalence, Molecular Features, and Therapeutic Opportunities
Aaron Tzvi Ciner et al.
MOLECULAR CANCER RESEARCH (2023)
Pancreatic Adenocarcinoma Management
Yan Jiang et al.
JCO ONCOLOGY PRACTICE (2023)
First data for sotorasib in patients with pancreatic cancer with KRAS p.G12C mutation: A phase I/II study evaluating efficacy and safety
John H Strickler et al.
JOURNAL OF CLINICAL ONCOLOGY (2022)
Neoadjuvant and adjuvant antitumor vaccination alone or combination with PD1 blockade and CD137 agonism in patients with resectable pancreatic adenocarcinoma
Thatcher Ross Heumann et al.
JOURNAL OF CLINICAL ONCOLOGY (2022)
Nanocarriers for pancreatic cancer imaging, treatments, and immunotherapies
Luman Liu et al.
THERANOSTICS (2022)
Molecular Characterization of KRAS Wild-type Tumors in Patients with Pancreatic Adenocarcinoma
Philip A. Philip et al.
CLINICAL CANCER RESEARCH (2022)
Stereotactic body radiotherapy plus pembrolizumab and trametinib versus stereotactic body radiotherapy plus gemcitabine for locally recurrent pancreatic cancer after surgical resection: an open-label, randomised, controlled, phase 2 trial
Xiaofei Zhu et al.
LANCET ONCOLOGY (2022)
Nimotuzumab combined with gemcitabine versus gemcitabine in K-RAS wild-type locally advanced or metastatic pancreatic cancer: A prospective, randomized-controlled, double-blinded, multicenter, and phase III clinical trial.
Shukui Qin et al.
JOURNAL OF CLINICAL ONCOLOGY (2022)
Diabetes Mellitus and Pancreatic Ductal Adenocarcinoma-Prevalence, Clinicopathological Variables, and Clinical Outcomes
Anna Badowska-Kozakiewicz et al.
CANCERS (2022)
The Role of the Microbiome in Pancreatic Cancer
Koji Miyabayashi et al.
CANCERS (2022)
Exceptional Response to Olaparib and Pembrolizumab for Pancreatic Adenocarcinoma With Germline BRCA1 Mutation and High Tumor Mutation Burden: Case Report and Literature Review
Joanne Lundy et al.
JCO PRECISION ONCOLOGY (2022)
FDAApproval Summary: Olaparib Monotherapy or in Combination with Bevacizumab for the Maintenance Treatment of Patients with Advanced Ovarian Cancer
Shaily Arora et al.
ONCOLOGIST (2021)
Inhibition of Hedgehog Signaling Alters Fibroblast Composition in Pancreatic Cancer
Nina G. Steele et al.
CLINICAL CANCER RESEARCH (2021)
Advances in the epidemiology of pancreatic cancer: Trends, risk factors, screening, and prognosis
Jie Cai et al.
CANCER LETTERS (2021)
KRAS Inhibitors- yes but what next? Direct targeting of KRAS- vaccines, adoptive T cell therapy and beyond
Misako Nagasaka et al.
CANCER TREATMENT REVIEWS (2021)
Randomized Phase II Study of PARP Inhibitor ABT-888 (Veliparib) with Modified FOLFIRI versus FOLFIRI as Second-line Treatment of Metastatic Pancreatic Cancer: SWOG S1513
E. Gabriela Chiorean et al.
CLINICAL CANCER RESEARCH (2021)
Phase II study of selumetinib, an orally active inhibitor of MEK1 and MEK2 kinases, in KRASG12R-mutant pancreatic ductal adenocarcinoma
Cara Kenney et al.
INVESTIGATIONAL NEW DRUGS (2021)
Overall survival from the phase 3 POLO trial: Maintenance olaparib for germline BRCA-mutated metastatic pancreatic cancer.
Talia Golan et al.
JOURNAL OF CLINICAL ONCOLOGY (2021)
Randomized phase II trial of olaparib plus pembrolizumab versus olaparib alone as maintenance therapy in metastatic pancreatic cancer patients with germline BRCA1 or BRCA2 (gBRCA1/2+) mutations: SWOG S2001
Vincent Chung et al.
JOURNAL OF CLINICAL ONCOLOGY (2021)
Sunitinib Alone or After Nephrectomy for Patients with Metastatic Renal Cell Carcinoma: Is There Still a Role for Cytoreductive Nephrectomy?
Arnaud Mejean et al.
EUROPEAN UROLOGY (2021)
Neoadjuvant and adjuvant immunotherapy in renal cell carcinoma
Alberto Martini et al.
WORLD JOURNAL OF UROLOGY (2021)
KRAS mutation in pancreatic cancer
Ji Luo
SEMINARS IN ONCOLOGY (2021)
TGF-β Signaling and Resistance to Cancer Therapy
Maoduo Zhang et al.
FRONTIERS IN CELL AND DEVELOPMENTAL BIOLOGY (2021)
Pancreatic cancer epidemiology: understanding the role of lifestyle and inherited risk factors
Alison P. Klein
NATURE REVIEWS GASTROENTEROLOGY & HEPATOLOGY (2021)
Drug delivery strategies in maximizing anti-angiogenesis and anti-tumor immunity
Victoria Lai et al.
ADVANCED DRUG DELIVERY REVIEWS (2021)
The role of the bacterial microbiome in the treatment of cancer
Zi-Kun Yu et al.
BMC CANCER (2021)
The role of microbiome in pancreatic cancer
Jenny Jing Li et al.
CANCER AND METASTASIS REVIEWS (2021)
Targeting KRAS in pancreatic cancer: new drugs on the horizon
Sahar F. Bannoura et al.
CANCER AND METASTASIS REVIEWS (2021)
BRCA mutations in pancreatic cancer and progress in their targeting
Samer Alkassis et al.
EXPERT OPINION ON THERAPEUTIC TARGETS (2021)
Pancreatic Cancer: A Review
Wungki Park et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2021)
Near Complete Pathologic Response to PD-1 Inhibitor and Radiotherapy in a Patient with Locally Advanced Pancreatic Ductal Adenocarcinoma
Patrick M. McCarthy et al.
ONCOTARGETS AND THERAPY (2021)
Identification of Targetable Gene Fusions and Structural Rearrangements to Foster Precision Medicine in KRAS Wild-Type Pancreatic Cancer
Michael J. Fusco et al.
JCO PRECISION ONCOLOGY (2021)
Cobimetinib Plus Gemcitabine: An Active Combination in KRAS G12R-Mutated Pancreatic Ductal Adenocarcinoma Patients in Previously Treated and Failed Multiple Chemotherapies
Bach Ardalan et al.
JOURNAL OF PANCREATIC CANCER (2021)
From state-of-the-art treatments to novel therapies for advanced-stage pancreatic cancer
Christopher Nevala-Plagemann et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2020)
Ipilimumab and Gemcitabine for Advanced Pancreatic Cancer: A Phase Ib Study
Suneel D. Kamath et al.
ONCOLOGIST (2020)
Phase 2 study of vismodegib, a hedgehog inhibitor, combined with gemcitabine and nab-paclitaxel in patients with untreated metastatic pancreatic adenocarcinoma
Ana De Jesus-Acosta et al.
BRITISH JOURNAL OF CANCER (2020)
Novel therapeutic strategies and perspectives for metastatic pancreatic cancer: vaccine therapy is more than just a theory
Wenhao Luo et al.
CANCER CELL INTERNATIONAL (2020)
PARP and PARG inhibitors in cancer treatment
Dea Slade
GENES & DEVELOPMENT (2020)
The potential role of chitosan-based nanoparticles as drug delivery systems in pancreatic cancer
Fatemeh Sadoughi et al.
IUBMB LIFE (2020)
Current and emerging therapies for patients with advanced pancreatic ductal adenocarcinoma: a bright future
Eric S Christenson et al.
LANCET ONCOLOGY (2020)
PARP inhibitors in pancreatic cancer: molecular mechanisms and clinical applications
Heng Zhu et al.
MOLECULAR CANCER (2020)
Role of oncogenic KRAS in the diagnosis, prognosis and treatment of pancreatic cancer
Louis Buscail et al.
NATURE REVIEWS GASTROENTEROLOGY & HEPATOLOGY (2020)
Cancer vaccines: Targeting KRAS-driven cancers
Ying Zhang et al.
EXPERT REVIEW OF VACCINES (2020)
Enhancing the Efficacy of CAR T Cells in the Tumor Microenvironment of Pancreatic Cancer
Janina Henze et al.
CANCERS (2020)
The tumour microenvironment in pancreatic cancer - clinical challenges and opportunities
Won Jin Ho et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2020)
Precision medicine phase II study evaluating the efficacy of a double immunotherapy by durvalumab and tremelimumab combined with olaparib in patients with solid cancers and carriers of homologous recombination repair genes mutation in response or stable after olaparib treatment
Jean-David Fumet et al.
BMC CANCER (2020)
Immunotherapy for pancreatic cancer: A 2020 update
Dimitrios Schizas et al.
CANCER TREATMENT REVIEWS (2020)
Transient stealth coating of liver sinusoidal wall by anchoring two-armed PEG for retargeting nanomedicines
Anjaneyulu Dirisala et al.
SCIENCE ADVANCES (2020)
Challenges and Opportunities for Pancreatic Cancer Immunotherapy
Adham S. Bear et al.
CANCER CELL (2020)
The Immune Microenvironment in Pancreatic Cancer
Magdalena Huber et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2020)
KRASG12C Inhibition with Sotorasib in Advanced Solid Tumors
David S. Hong et al.
NEW ENGLAND JOURNAL OF MEDICINE (2020)
The Emerging Role of Microbiota and Microbiome in Pancreatic Ductal Adenocarcinoma
Sona Ciernikova et al.
BIOMEDICINES (2020)
Pancreatic Cancer: A Review of Risk Factors, Diagnosis, and Treatment
ZhiYu Zhao et al.
TECHNOLOGY IN CANCER RESEARCH & TREATMENT (2020)
KRAS wild-type pancreatic ductal adenocarcinoma: molecular pathology and therapeutic opportunities
Claudio Luchini et al.
JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH (2020)
Angiogenesis in pancreatic cancer: current research status and clinical implications
Shuo Li et al.
ANGIOGENESIS (2019)
FDA Approval Summary: Pembrolizumab for the Treatment of Microsatellite Instability-High Solid Tumors
Leigh Marcus et al.
CLINICAL CANCER RESEARCH (2019)
Early Detection of Pancreatic Cancer: Opportunities and Challenges
Aatur D. Singhi et al.
GASTROENTEROLOGY (2019)
Phase IB/II Randomized Study of FOLFIRINOX Plus Pegylated Recombinant Human Hyaluronidase Versus FOLFIRINOX Alone in Patients With Metastatic Pancreatic Adenocarcinoma: SWOG S1313
Ramesh K. Ramanathan et al.
JOURNAL OF CLINICAL ONCOLOGY (2019)
Angiogenesis in Pancreatic Cancer: Pre-Clinical and Clinical Studies
Tiziana Annese et al.
CANCERS (2019)
Results from a Phase IIb, Randomized, Multicenter Study of GVAX Pancreas and CRS-207 Compared with Chemotherapy in Adults with Previously Treated Metastatic Pancreatic Adenocarcinoma (ECLIPSE Study)
Dung T. Le et al.
CLINICAL CANCER RESEARCH (2019)
NRG1 Gene Fusions Are Recurrent, Clinically Actionable Gene Rearrangements in KRAS Wild-Type Pancreatic Ductal Adenocarcinoma
Martin R. Jones et al.
CLINICAL CANCER RESEARCH (2019)
Maintenance Olaparib for Germline BRCA-Mutated Metastatic Pancreatic Cancer
Talia Golan et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
Checkpoint inhibitors in pancreatic cancer
Andreas Henriksen et al.
CANCER TREATMENT REVIEWS (2019)
Broadening the Impact of Immunotherapy to Pancreatic Cancer: Challenges and Opportunities
Vinod P. Balachandran et al.
GASTROENTEROLOGY (2019)
State-of-the-art strategies for targeting the DNA damage response in cancer
Patrick G. Pilie et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2019)
Gut microbiome and CAR-T therapy
Muhammad Bilal Abid et al.
EXPERIMENTAL HEMATOLOGY & ONCOLOGY (2019)
Harnessing the Microbiome for Pancreatic Cancer Immunotherapy
Gerardo A. Vitiello et al.
TRENDS IN CANCER (2019)
Block Copolymer Micelles in Nanomedicine Applications
Horacio Cabral et al.
CHEMICAL REVIEWS (2018)
HALO 202: Randomized Phase II Study of PEGPH20 Plus Nab- Paclitaxel/Gemcitabine Versus Nab- Paclitaxel/Gemcitabine in Patients With Untreated, Metastatic Pancreatic Ductal Adenocarcinoma
Sunil R. Hingorani et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
Understanding the tumor immune microenvironment (TIME) for effective therapy
Mikhail Binnewies et al.
NATURE MEDICINE (2018)
The Pancreatic Cancer Microbiome Promotes Oncogenesis by Induction of Innate and Adaptive Immune Suppression
Smruti Pushalkar et al.
CANCER DISCOVERY (2018)
NRG1 Fusions in KRAS Wild-Type Pancreatic Cancer
Christoph Heining et al.
CANCER DISCOVERY (2018)
Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries
Freddie Bray et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2018)
Immunotherapy for melanoma
Lauren M. Cuevas et al.
SEMINARS IN CUTANEOUS MEDICINE AND SURGERY (2018)
The Potential of CAR T Cell Therapy in Pancreatic Cancer
Mehmet Akce et al.
FRONTIERS IN IMMUNOLOGY (2018)
Immunotherapy and Prevention of Pancreatic Cancer
Alexander H. Morrison et al.
TRENDS IN CANCER (2018)
Intratumoral bacteria may elicit chemoresistance by metabolizing anticancer agents
Leore T. Geller et al.
MOLECULAR & CELLULAR ONCOLOGY (2018)
Meta-analysis of the impact of neoadjuvant therapy on patterns of recurrence in pancreatic ductal adenocarcinoma
S. Schorn et al.
BJS OPEN (2018)
PD-L1 blockade enhances response of pancreatic ductal adenocarcinoma to radiotherapy
Abul Azad et al.
EMBO MOLECULAR MEDICINE (2017)
Targeting stroma in pancreatic cancer: Promises and failures of targeted therapies
Afsane Bahrami et al.
JOURNAL OF CELLULAR PHYSIOLOGY (2017)
CAR T-cell therapy for pancreatic cancer
Carl J. DeSelm et al.
JOURNAL OF SURGICAL ONCOLOGY (2017)
Identification of Targetable ALK Rearrangements in Pancreatic Ductal Adenocarcinoma
Aatur D. Singhi et al.
JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK (2017)
Potential role of intratumor bacteria in mediating tumor resistance to the chemotherapeutic drug gemcitabine
Leore T. Geller et al.
SCIENCE (2017)
PARP inhibitors: Synthetic lethality in the clinic
Christopher J. Lord et al.
SCIENCE (2017)
Bevacizumab in Colorectal Cancer: Current Role in Treatment and the Potential of Biosimilars
Lee S. Rosen et al.
TARGETED ONCOLOGY (2017)
Multi-institutional Validation Study of the American Joint Commission on Cancer (8th Edition) Changes for Tand N Staging in Patients With Pancreatic Adenocarcinoma
Peter J. Allen et al.
ANNALS OF SURGERY (2017)
Cancer nanomedicine: progress, challenges and opportunities
Jinjun Shi et al.
NATURE REVIEWS CANCER (2017)
PARP Inhibitor Upregulates PD-L1 Expression and Enhances Cancer-Associated Immunosuppression
Shiping Jiao et al.
CLINICAL CANCER RESEARCH (2017)
Irinotecan Delivery by Lipid-Coated Mesoporous Silica Nanoparticles Shows Improved Efficacy and Safety over Liposomes for Pancreatic Cancer
Xiangsheng Liu et al.
ACS NANO (2016)
Randomised, open-label, phase II study of gemcitabine with and without IMM-101 for advanced pancreatic cancer
Angus G. Dalgleish et al.
BRITISH JOURNAL OF CANCER (2016)
Pharmacokinetics and pharmacogenetics of Gemcitabine as a mainstay in adult and pediatric oncology: an EORTC-PAMM perspective
Joseph Ciccolini et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2016)
Targeting KRAS for diagnosis, prognosis, and treatment of pancreatic cancer: Hopes and realities
Barbara Bournet et al.
EUROPEAN JOURNAL OF CANCER (2016)
Mechanism of hard-nanomaterial clearance by the liver
Kim M. Tsoi et al.
NATURE MATERIALS (2016)
Epidemiology of pancreatic cancer
Milena Ilic et al.
WORLD JOURNAL OF GASTROENTEROLOGY (2016)
Cancer of the pancreas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-upaEuro
M. Ducreux et al.
ANNALS OF ONCOLOGY (2015)
Nintedanib, a triple angiokinase inhibitor, enhances cytotoxic therapy response in pancreatic cancer
Niranjan Awasthi et al.
CANCER LETTERS (2015)
Desmoplasia in Primary Tumors and Metastatic Lesions of Pancreatic Cancer
Clifford J. Whatcott et al.
CLINICAL CANCER RESEARCH (2015)
Randomized Phase Ib/II Study of Gemcitabine Plus Placebo or Vismodegib, a Hedgehog Pathway Inhibitor, in Patients With Metastatic Pancreatic Cancer
Daniel V. T. Catenacci et al.
JOURNAL OF CLINICAL ONCOLOGY (2015)
Ternary polyplex micelles with PEG shells and intermediate barrier to complexed DNA cores for efficient systemic gene delivery
Junjie Li et al.
JOURNAL OF CONTROLLED RELEASE (2015)
PD-1/PD-L1 Blockade Together With Vaccine Therapy Facilitates Effector T-Cell Infiltration Into Pancreatic Tumors
Kevin C. Soares et al.
JOURNAL OF IMMUNOTHERAPY (2014)
A phase I dose escalation trial of tremelimumab (CP-675,206) in combination with gemcitabine in chemotherapy-naive patients with metastatic pancreatic cancer
M. Aglietta et al.
ANNALS OF ONCOLOGY (2014)
Optimized rod length of polyplex micelles for maximizing transfection efficiency and their performance in systemic gene therapy against stroma-rich pancreatic tumors
Anjaneyulu Dirisala et al.
BIOMATERIALS (2014)
Gene therapy in pancreatic cancer
Si-Xue Liu et al.
WORLD JOURNAL OF GASTROENTEROLOGY (2014)
IMM-101, an immunotherapeutic agent in clinical development as an adjunctive treatment for pancreatic cancer
Hilary Bilyard et al.
Journal for ImmunoTherapy of Cancer (2014)
Roles for KRAS in Pancreatic Tumor Development and Progression
Marina Pasca di Magliano et al.
GASTROENTEROLOGY (2013)
Hyaluronan impairs vascular function and drug delivery in a mouse model of pancreatic cancer
Michael A. Jacobetz et al.
GUT (2013)
Combining Radiotherapy and Cancer Immunotherapy: A Paradigm Shift
Silvia C. Formenti et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2013)
BIBF 1120 (Nintedanib), a Triple Angiokinase Inhibitor, Induces Hypoxia but not EMT and Blocks Progression of Preclinical Models of Lung and Pancreatic Cancer
Bercin Kutluk Cenik et al.
MOLECULAR CANCER THERAPEUTICS (2013)
Increased Survival in Pancreatic Cancer with nab-Paclitaxel plus Gemcitabine
Daniel D. Von Hoff et al.
NEW ENGLAND JOURNAL OF MEDICINE (2013)
Experimental studies on treatment of pancreatic cancer with double-regulated duplicative adenovirus AdTPHre-hEndo carrying human endostatin gene
Yun-feng Shan et al.
PANCREATOLOGY (2013)
Angiotensin inhibition enhances drug delivery and potentiates chemotherapy by decompressing tumour blood vessels
Vikash P. Chauhan et al.
NATURE COMMUNICATIONS (2013)
Accumulation of sub-100 nm polymeric micelles in poorly permeable tumours depends on size
H. Cabral et al.
NATURE NANOTECHNOLOGY (2011)
Principles and mechanisms of vessel normalization for cancer and other angiogenic diseases
Peter Carmeliet et al.
NATURE REVIEWS DRUG DISCOVERY (2011)
FOLFIRINOX versus Gemcitabine for Metastatic Pancreatic Cancer
Thierry Conroy et al.
NEW ENGLAND JOURNAL OF MEDICINE (2011)
Understanding the molecular-based mechanism of action of the tyrosine kinase inhibitor: sunitinib
Alfredo Carrato Mena et al.
ANTI-CANCER DRUGS (2010)
Strategies in the design of nanoparticles for therapeutic applications
Robby A. Petros et al.
NATURE REVIEWS DRUG DISCOVERY (2010)
Comparison of the effects of the kinase inhibitors imatinib, sorafenib, and transforming growth factor-beta receptor inhibitor on extravasation of nanoparticles from neovasculature
Mitsunobu R. Kano et al.
CANCER SCIENCE (2009)
Nanocarriers as an emerging platform for cancer therapy
Dan Peer et al.
NATURE NANOTECHNOLOGY (2007)
Opsonization, biodistribution, and pharmacokinetics of polymeric nanoparticles
DE Owens et al.
INTERNATIONAL JOURNAL OF PHARMACEUTICS (2006)
5-Fluorouracil: Mechanisms of action and clinical strategies
DB Longley et al.
NATURE REVIEWS CANCER (2003)
Share Paper
